Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629198 | 0.88 | MAPT (0.47) | MAPTKMT2AMEN1ABCG2NPC1 | |
| SCHEMBL1629833 | 0.83 | POLB (0.40) | MAPTKMT2AMEN1HTT | |
| SCHEMBL1629692 | 0.82 | MAPT (0.52) | MAPTTLR9NPSR1LMNAKDM4E | |
| SCHEMBL15559248 | 0.82 | APP (0.51) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL12722760 | 0.81 | MAPT (0.51) | MAPTTLR9KMT2AMEN1NPC1 | |
| SCHEMBL1630485 | 0.77 | MAPT (0.49) | MAPTKMT2AMEN1LMNAKDM4E | |
| SCHEMBL1629144 | 0.76 | PIK3CD (0.49) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16442402 | 0.76 | HTT (0.51) | MAPTKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL10169410 | 0.76 | APP (0.55) | MAPTTLR9KMT2AMEN1NPC1 | |
| SCHEMBL1628989 | 0.75 | ADORA3 (0.50) | MAPTKMT2AMEN1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | claimed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | claimed |
| EP-1776346-A1 | 1,5-DIPHENYLPYRAZOLES | Merck Patent GmbH (DE) | 2007-04-25 | — | — | EP | claimed |
| WO-2006018082-A1 | 1,5-DIPHENYLPYRAZOLES | MERCK PATENT GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
| EP-1776346-A1 | 1,5-DIPHENYLPYRAZOLES | Merck Patent GmbH (DE) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006018082-A1 | 1,5-DIPHENYLPYRAZOLES | MERCK PATENT GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 2299/4885TLR9 4235/4885KMT2A 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.